The research, led by Yingchu Dai, Yufan Ling and Lu Hou with senior authorship from Leyuan Zhou, Hailong Pei and Wanshi Li, began with a retrospective analysis of 77 patients with non-small cell lung cancer, the most common form of lung malignancy worldwide. The team stratified the cohort according to serum triglyceride levels and followed outcomes over time. The differences were stark. Patients whose triglycerides exceeded 2.3 millimoles per litre showed significantly shorter overall survival than those in the normal range below 1.7 millimoles per litre, a difference that reached statistical significance with a log-rank p-value of 0.009. More striking still were the metastasis rates: 84.4 percent of hypertriglyceridemic patients displayed lymph node metastasis compared with just 37.9 percent of normotriglyceridemic patients, and distant metastasis was detected in 31.3 percent versus 3.4 percent respectively.

Those clinical associations set the stage for the mechanistic work. To test whether high triglycerides were merely a marker of poor health or an active participant in cancer progression, the researchers modelled hypertriglyceridemia in mice and examined how lung tumours behaved under those conditions. The animal data reinforced the human findings, showing reduced survival in tumour-bearing mice with elevated triglycerides. The team then turned to controlled laboratory systems, using extracellular matrix constrained invasion assays in non-small cell lung cancer cell lines. These assays recreate a critical physical barrier that metastasising cells must overcome in the body: the dense network of collagen and other proteins that forms the extracellular matrix, the biological scaffolding that anchors tissues together and that a migrating tumour cell must physically breach.

It is within this constrained microenvironment that the study’s central discovery emerges. The researchers found that triglycerides enhance lipid beta-oxidation, the cellular process by which fatty acids are broken down in mitochondria to generate energy. Rather than serving simply as inert fuel, this surge of lipid catabolism appeared to activate a signalling pathway centred on RhoA, a small GTP-binding protein well known to cell biologists as a master regulator of the actin cytoskeleton. When RhoA signalling intensified, tumour cells remodelled their internal scaffolding of actin filaments, gaining the mechanical force and structural plasticity needed to deform their bodies, push through narrow gaps in the matrix, and acquire what the authors describe as metastatic competence.

The technical logic of this axis deserves close attention. Triglycerides stored in lipid droplets must first be mobilised and transported into mitochondria, a step that depends on CPT1A, also known as CPT1A or carnitine palmitoyltransferase 1A, the rate-limiting enzyme of fatty acid import into mitochondria. The study’s figures trace this progression carefully: elevated neutral lipid levels enhanced tumour invasion potential in matrix-based assays, lipid depletion proved to be a prerequisite for tumour cell metastasis, and metastasising cells exhibited both enhanced lipid metabolism and pronounced actin cytoskeleton remodelling. Perhaps most intriguingly, the team found that RhoA promotes metastasis by enhancing the transcriptional activity of CPT1A, suggesting a feed-forward loop in which cytoskeletal signalling amplifies the very lipid-burning machinery that activates it.

To establish causality rather than mere correlation, the researchers deployed both pharmacological inhibition and genetic silencing. When they blocked CPT1A or RhoA, either with drugs or by knocking down the genes that encode them, the triglyceride-driven invasion and metastasis were significantly suppressed. This dual approach matters because it demonstrates that the lipid beta-oxidation and RhoA-driven cytoskeletal remodelling axis is not simply associated with metastatic behaviour but is functionally required for it. Interrupting the pathway at either node collapses the pro-metastatic effect of elevated triglycerides, which is precisely the kind of evidence needed to justify pursuing these molecules as therapeutic targets.

The findings sit within a rapidly expanding body of literature on cancer metabolism and metastasis. Previous work has shown that the fatty acid receptor CD36 marks metastasis-initiating cells in oral cancer, that the enzymes ACSL4 and polyunsaturated lipids support metastatic extravasation and colonisation, and that mechanical cues from the extracellular matrix can regulate lipid metabolism through the Lipin-1 and SREBP pathways. The new study adds an important directional insight: lipids are not only passive building blocks or energy reserves for migrating cells but can actively trigger the mechanical programming that makes migration possible. The link between membrane lipid milieu and Rho-family signalling had been hinted at in earlier work on peroxisomal beta-oxidation, and the cytoskeleton’s role in controlling lipid droplet movement and storage has been documented, but the demonstration that this circuitry operates in the context of systemic hypertriglyceridemia and lung cancer metastasis is novel.

The clinical implications are potentially significant. Elevated serum triglycerides are extraordinarily common, driven by diet, obesity, diabetes and genetic factors, and they are already a recognised risk factor for cardiovascular disease. If the mechanism described here holds in broader patient populations, then triglyceride management could become a meaningful component of supportive care in non-small cell lung cancer, and lipid-lowering interventions might be evaluated not only for heart health but for their potential to reduce metastatic risk. More immediately, the identification of CPT1A and RhoA as druggable nodes in the pathway suggests that inhibitors of fatty acid oxidation, some of which are already in clinical development for other cancers, could be repurposed or combined with existing treatments for patients with hypertriglyceridemia-associated lung tumours.

Important caveats remain. The human component of the study was retrospective and involved a relatively modest cohort of 77 patients, so prospective validation in larger and more diverse populations will be essential before triglyceride levels can be incorporated into prognostic models or treatment decisions. The mouse and cell-line experiments, while mechanistically rigorous, capture only parts of the complexity of human tumour biology, and the interplay between triglycerides, immune cells, the lymphatic vasculature and other microenvironmental factors remains to be fully explored. The authors also note that their data were generated with appropriate ethical oversight, with approval from the Ethics Committee of Soochow University and informed consent from all patients, and that datasets are available from the corresponding author upon reasonable request.

Nevertheless, the study represents a compelling example of how a systemic metabolic condition can be connected, step by step, to the cellular physics of cancer spread. By showing that triglycerides fuel beta-oxidation, that beta-oxidation activates RhoA, and that RhoA-driven cytoskeletal remodelling enables tumour cells to overcome the mechanical constraints of the extracellular matrix, the researchers have transformed a statistical association into a testable, targetable pathway. As metastasis remains the leading cause of death in lung cancer, strategies that target lipid catabolism and cytoskeletal dynamics may open a new front in the effort to keep the disease localised, offering hope that something as routine as a blood lipid panel could one day help identify which patients need the most aggressive intervention.

Subject of Research: The role of triglyceride-driven lipid beta-oxidation and RhoA cytoskeletal signalling in non-small cell lung cancer metastasis

Article Title: Triglyceride enhancs NSCLC metastasis via lipid β-oxidation by RhoA-driven cytoskeletal remodeling in ECM-constrained microenvironments

Article References: Dai, Y., Ling, Y., Hou, L., Yang, T., Gu, Q., Fang, Y., Li, W., Pei, H., & Zhou, L. (2026). Triglyceride enhancs NSCLC metastasis via lipid β-oxidation by RhoA-driven cytoskeletal remodeling in ECM-constrained microenvironments. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03586-9

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03586-9

Keywords: non-small cell lung cancer, triglycerides, metastasis, lipid beta-oxidation, RhoA, CPT1A, cytoskeleton, extracellular matrix, cancer metabolism, hypertriglyceridemia, British Journal of Cancer, Triglyceride

The study, published in the journal Angiogenesis, focuses on a long-standing puzzle in cancer biology: how tumors recruit and remodel blood vessels to sustain their growth. Tumors cannot enlarge beyond a few millimeters without recruiting new vasculature, a process known as tumor angiogenesis. The vessels that form inside tumors are typically abnormal — leaky, tortuously branched, and poorly covered by supportive pericyte cells — which creates hypoxic, acidic conditions that paradoxically stimulate even more angiogenic signalling, most notably through vascular endothelial growth factor, or VEGF, and its receptor VEGFR2. The new work reveals that Epac1 sits at a central junction of this process, coordinating both the chemical VEGF signals and the mechanical forces that shape tumor vessel formation.

Epac1, encoded by the gene RAPGEF3, is a guanine nucleotide exchange factor activated by the intracellular messenger cyclic AMP. It exists in two isoforms, but only Epac1 is expressed in endothelial cells, where it participates in regulating junctional dynamics and cell polarity. To determine whether Epac1 matters in tumor angiogenesis specifically, the team first analyzed publicly available single-cell RNA sequencing data from human primary melanomas and healthy human skin. They found that RAPGEF3 expression was markedly enriched in the endothelial cells of melanoma tissue compared with the endothelium of healthy skin, and that the gene was predominantly active in vascular rather than lymphatic endothelial cells. This human evidence suggested that the protein might be a genuine feature of the tumor vasculature rather than an artifact of experimental models.

The researchers then turned to mouse models. In mice lacking Epac1 throughout the body, subcutaneously implanted B16F10 melanoma cells still formed palpable tumors, but growth slowed dramatically after day fourteen — precisely the stage at which vascularization becomes the limiting factor for tumor expansion. By day eighteen, tumors in the knockout animals were roughly half the size of those in normal mice, and staining for the endothelial marker CD31 revealed a significantly smaller vascular area within them. Because global deletion could not distinguish effects in blood vessel cells from effects in other stromal cells, the team generated a second mouse line in which Epac1 could be deleted selectively in endothelial cells using a tamoxifen-inducible Cre system. The result was the same: reduced tumor volume and reduced vascularization, confirming that the endothelial supply of Epac1 itself drives melanoma growth.

To understand the molecular mechanism, the researchers isolated tumor endothelial cells from the melanomas and performed whole-transcriptome sequencing. In the Epac1-deficient vessels, gene ontology analysis showed broad downregulation of angiogenesis-associated pathways, including sprouting angiogenesis, endothelial cell migration, and proliferation. Key pro-angiogenic genes such as Kdr (which encodes VEGFR2), Angpt1, Hif1a, Dll1, and Dll4 were all reduced. Strikingly, the analysis also revealed suppressed expression of canonical target genes of the transcriptional co-activators YAP and TAZ — including Ccn1, Ccn2, and Ankrd1 — pointing to a previously unknown connection between Epac1 and the Hippo signalling pathway in tumor vessels.

YAP and TAZ are mechanosensitive transcriptional regulators that act as major effectors of the Hippo pathway. Their activity depends less on how much protein is present and more on where the protein resides: when they translocate into the nucleus, they partner with TEAD-family transcription factors to switch on genes that promote cell proliferation, migration, and survival. In the Epac1-deficient endothelial cells, the researchers found that total YAP and TAZ protein levels were unchanged, but nuclear localization was significantly reduced, and TEAD-dependent reporter activity was markedly diminished. A parallel experiment using a selective pharmacological inhibitor of Epac1’s enzymatic activity in human umbilical vein endothelial cells produced the same suppression of YAP/TAZ target gene expression, confirming that the catalytic function of the protein is required to maintain this transcriptional program.

The team then traced how Epac1 links VEGF signalling to YAP/TAZ activation. In control endothelial cells, VEGF stimulation robustly induced expression of Vegfr2 and Ccn2, activated the small GTPase RhoA, and promoted phosphorylation of myosin light chain 2, a key downstream target of the RhoA effector kinase ROCK. In Epac1-deficient cells, all of these responses were blunted or abolished. Pharmacological inhibition of RhoA with C3 transferase reduced TEAD-driven transcription and suppressed VEGF-induced Ccn2 expression, while VEGF-driven nuclear translocation of YAP and TAZ in human endothelial cells was fully prevented by RhoA inhibition. Together, these experiments establish a signalling chain running from Epac1 through VEGFR2, RhoA, and the actin cytoskeleton to the nucleus, where YAP and TAZ execute their pro-angiogenic gene program.

Perhaps the most striking findings concerned mechanosensing — the ability of endothelial cells to respond to physical forces such as blood flow. Tumor vessels experience disturbed, oscillatory flow patterns that promote pro-angiogenic signalling and metastasis. Using an in vitro system that applies oscillatory shear stress to endothelial monolayers, the researchers showed that control cells aligned themselves with the direction of flow, whereas Epac1-deficient cells completely failed to do so. Under the same conditions, oscillatory shear stress normally increases the interaction between VE-cadherin, the junctional adhesion protein, and VEGFR2 — a partnership thought to form part of the endothelial mechanosensory complex. Proximity ligation assays revealed that this interaction was abolished in Epac1-deficient cells, as was shear-induced phosphorylation of VE-cadherin at tyrosine 658, an essential modification for mechanosensing, and the shear-induced nuclear accumulation of YAP and TAZ. When the researchers reintroduced Epac1 into the knockout cells using lentiviral vectors, VEGFR2 and Ccn2 expression, VEGF responses, and flow-induced alignment were all rescued, confirming the specificity of the effect.

The study also carries an important nuance about Epac1’s role in vascular biology. Previous work by the same group and others has shown that Epac1 is dispensable during physiological angiogenesis — the retinal vascular area of Epac1-deficient mice at postnatal day five is comparable to that of wild-type animals — yet pathological neovascularization in oxygen-induced retinopathy is significantly reduced without the protein. The new melanoma data fit this pattern: endogenous endothelial Epac1 appears to be largely irrelevant for normal vascular maintenance but becomes functionally indispensable in pathological settings characterized by excessive VEGF signalling and altered mechanical cues. This context-dependence is encouraging from a therapeutic standpoint, because it suggests that drugs targeting Epac1 might impair tumor vessel growth while sparing the normal vasculature, potentially reducing the side effects that complicate current anti-angiogenic therapies.

The authors caution that their study used melanoma as the tumor model, and that the prominent upregulation of Epac1 in tumor endothelium and its consequences for tumor growth may not generalize to all cancer types. Nevertheless, the identification of Epac1 as a central modulator that integrates VEGF signalling, RhoA-dependent cytoskeletal dynamics, YAP/TAZ transcription, and flow mechanosensing provides the most complete mechanistic picture to date of how a single endothelial protein can orchestrate pathological tumor vascularization. With Epac inhibitors already under investigation for other cancers, the prospect of starving melanomas by dismantling the molecular machinery of their blood vessels has moved a tangible step closer to the clinic.

Subject of Research: The role of endothelial Epac1 in regulating VEGFR2 and YAP/TAZ signalling during melanoma angiogenesis

Article Title: Endothelial Epac1 facilitates YAP/TAZ controlled melanoma growth and angiogenesis

Article References: Wibowo, Y. C., Ma, N., Ren, Y., Cordero, J., Gahn, J., Chen, Z., Levay, M., Ola, R., Feng, Y., Dobreva, G., Langer, H., Wieland, T., Vettel, C., & Jansen, S. (2026). Endothelial Epac1 facilitates YAP/TAZ controlled melanoma growth and angiogenesis. Angiogenesis, 29(4), Article 72. https://doi.org/10.1007/s10456-026-10080-6

Image Credits: AI Generated

DOI: 10.1007/s10456-026-10080-6

Keywords: Epac1, melanoma, angiogenesis, tumor endothelial cells, VEGFR2, YAP/TAZ, Hippo signalling, RhoA, mechanotransduction, VE-cadherin, VEGF, skin cancer

ECT2, or epithelial cell transforming sequence 2, has long presented oncologists with a paradox. Across different cancer types it has been reported to behave sometimes as an oncogene that drives tumor growth and sometimes as a tumor suppressor that restrains it, with its effect apparently dictated by a mixture of intrinsic cellular factors and cues from the surrounding tumor microenvironment. What has been missing, the authors argue, is a clear picture of what ECT2 actually does in PTC, where its expression dynamics, clinical relevance and mechanism of action had remained poorly defined. The new work sets out to fill that gap with a combination of patient tissue analysis and mechanistic experiments in cell lines.

The team began by measuring ECT2 in surgical specimens from PTC patients using immunohistochemistry, a technique that reveals where proteins accumulate within tissue sections. They complemented this with quantitative real-time PCR and Western blotting to quantify messenger RNA and protein levels in PTC cell lines compared with normal thyroid epithelial cells. The results were consistent across methods: ECT2 was significantly upregulated in tumor cells, and high expression in patient tumors tracked closely with poor prognosis, marking the protein as a potential predictive biomarker for the disease.

To probe what ECT2 was actually doing, the researchers turned to loss-of-function experiments in two widely used PTC cell lines, TPC-1 and BCPAP. When they knocked down ECT2, the cells’ capacity to proliferate dropped sharply, as measured by CCK-8 assays and colony formation tests, which gauge both short-term metabolic activity and the ability of individual cells to establish expanding colonies. Transwell migration and invasion assays showed that ECT2 depletion also hampered the cells’ movement through artificial barriers, a laboratory proxy for the invasive behavior that makes cancers dangerous. Conversely, activating ECT2 signaling pushed proliferation in the opposite direction, confirming the protein’s role as a growth promoter in these cells.

The mechanistic heart of the study came from RNA sequencing, which allowed the team to survey the entire transcriptomic landscape of PTC cells with and without ECT2. That analysis revealed a dual regulatory scheme. On one side, ECT2 suppresses the lipoic acid pathway; on the other, it activates the PI3K/AKT pathway, a canonical growth-signaling route frequently hijacked in human cancers. Lipoic acid, a mitochondrial cofactor essential for energy-generating enzyme complexes, has emerged in recent years as a regulator of cellular metabolism, and its suppression by ECT2 suggests the protein is actively reshaping how thyroid tumor cells produce and spend energy.

The sequencing data pointed to a specific chain of events downstream of ECT2. The protein induces phosphorylation of RhoA, a small GTP-binding protein involved in cytoskeletal regulation, which in turn activates the transcription factor MYC, one of the most potent drivers of gene expression in proliferating cells. Activated MYC ramps up the expression of glycolysis-related genes, pushing the cells toward the fermentative glucose metabolism that characterizes the Warburg effect, the metabolic reprogramming that allows rapidly dividing tumors to generate biomass and signaling intermediates even in oxygen-rich conditions. In effect, ECT2 appears to rewire PTC cells’ energy economy from the top down, through a signaling cascade that connects a cytoskeletal regulator to one of cancer biology’s most influential transcription factors.

Perhaps the most clinically provocative finding concerns drug resistance. The researchers found that ECT2 downregulates drug influx transporters, the molecular gatekeepers that carry chemotherapeutic agents into cells, while simultaneously upregulating efflux transporters that pump drugs back out. The net effect is that tumor cells take in less medication and expel more of what does get in, raising the IC50 value, the drug concentration required to kill half the cells, and thereby rendering them measurably more resistant to treatment. This transport-based resistance mechanism operates independently of the metabolic reprogramming, giving ECT2 a second, parallel route to worsening patient outcomes.

Taken together, the findings recast ECT2 as a hub where growth signaling, metabolic reprogramming and drug transport converge in papillary thyroid carcinoma. The authors conclude that the protein drives PTC cell proliferation through its dual suppression of the lipoic acid pathway and activation of PI3K/AKT, while its effects on RhoA phosphorylation, MYC activation and glycolysis gene expression provide the metabolic fuel for unchecked growth, and its manipulation of transporters undermines chemotherapy. They emphasize that these discoveries offer a novel entry point for targeting the ECT2 signaling axis therapeutically, potentially combining metabolic interventions with strategies to restore drug sensitivity.

The study, supported by the Wuxi Double Hundred Top-notch Talent Program, also carries important caveats that the authors themselves acknowledge. The core mechanistic work was performed in cell lines, and while the clinical correlation between ECT2 expression and prognosis was established in patient specimens, the full pathway from protein to patient outcome will require further validation in animal models and larger clinical cohorts. The researchers call explicitly for continued mechanistic and translational investigation, noting that turning a biomarker discovery into a therapeutic strategy is a long road involving drug development, delivery optimization and careful patient stratification.

For a cancer that is often described as highly curable, papillary thyroid carcinoma nonetheless poses real challenges in the subset of patients with aggressive, treatment-refractory disease, and the identification of ECT2 as a driver of both proliferation and chemoresistance offers a molecular handle on that problem. If subsequent studies confirm that blocking ECT2 activity, or restoring lipoic acid pathway function, can sensitize tumors to existing drugs, the protein could become both a prognostic marker guiding treatment intensity and a target for combination therapies aimed at the metabolic vulnerabilities of hard-to-treat thyroid cancers.

Subject of Research: The role of ECT2 in regulating energy metabolism and chemoresistance in papillary thyroid carcinoma.

Article Title: ECT2 antagonizes lipoic acid to modulate papillary thyroid carcinoma progression through energy metabolism pathways

Article References: Huang, Z., Gao, Y., Wang, N., Cai, D., & Bai, N. (2026). ECT2 antagonizes lipoic acid to modulate papillary thyroid carcinoma progression through energy metabolism pathways. Cancer Cell International. https://doi.org/10.1186/s12935-026-04459-0

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04459-0

Keywords: ECT2, papillary thyroid carcinoma, lipoic acid, PI3K/AKT pathway, glycolysis, MYC, RhoA, chemoresistance, cancer metabolism, thyroid cancer, drug transporters, biomarker